Effect of Hsp90 inhibitors on Melan-A/MART-1 promoter-driven EGFP reporter.

a<p>Cell were treated for 3 days.</p>b<p>Dose indicated is optimal dose for antigen increase</p>c<p>Geometric mean of EGFP flow histogram.</p>d<p>Concenteration of Novobiocin in µM</p><p>Effect of Hsp90 inhibitors on Melan-A/MART-1 promoter-driven EGFP reporter.</p

Characterization of Hsp90 inhibition of MAPK signal transduction pathway and Melanoma-Associated Antigens.

<p>A. Western blot performed on extracts of the MU89 cell line treated as indicated for three days. Extracts were probed with antibodies to BRAF, Melan-A/MART-1, TRP-2, or β-Actin in rows top to bottom as indicated. 30 µg of total protein was loaded in each lane of the gel. 1.0 µg/ml of 17-AAG, 1.0 µg/ml of 17-AEP, or 2.5 µg/ml CCT018159 were used to treat the cells. B. Protein gel electrophoresis was performed using 30 µg of total protein extracts prepared from the indicated cell lines. Cells were untreated (control) or treated with 0.15 µg/ml of BIIB021 for three days. After transfer, Western blots were probed with antibodies to phosphorylated MEK (p-MEK) or β-Actin.</p

Dose response curves for various Hsp90 inhibitors.

<p>As in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114506#pone-0114506-g001" target="_blank">Fig.1</a>, reporter cells expressing EGFP-linked to the Melan-AMART-1 promoter were treated with a series of Hsp90 inhibitors. Filled diamonds: A375 antigen low Melan-A/MART-1 promoter EGFP reporter cell line. Open circles: MM96L+, high antigen-expressing Melan-A/MART-1 promoter EGFP reporter cell line. Data are from one representative experiment.</p